ClinicalTrials.gg
CompletedNCT01355068Updated Jan 28, 2021Results posted

A Study to Assess if Epanutin Infatabs 50 mg From Germany Are Similar to Dilantin Infatabs 50 mg From Australia

A Phase 1 interventional study of Epanutin Infatabs (Phenytoin) and Dilantin Infatabs (Phenytoin) in Healthy, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 1 site in Singapore. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Seizures by Viatris Inc. — none open to participants now, none under way, none of them phase 3. Seizures · Viatris Inc..

Enrollment
12th of 12
26 · median 261
Started
2011
with 2 others
Phase 1
Only one
of the 12
Registered
9th of 12
by date

Among the 12 studies in Seizures by Viatris Inc., this one is the 12th largest by enrollment, is one of 3 that started in 2011, is the only one in phase 1, and was the 9th registered.

Seizures

766 studies on the registry are indexed under Seizures; 134 are open to participants now.

Browse Seizures studies →

Open to participants now

None of the 12 studies in Seizures by Viatris Inc. is open now. The open studies under Seizures, anywhere →

Who these studies take

Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 21 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Seizures by Viatris Inc. as a file.
02

Study summary

In this study, the bioequivalence of Epanutin Infatabs® 50 mg (sourced from Germany) and Dilantin Infatabs® 50 mg (sourced from Australia) will be assessed. This is intended to be a pivotal bioequivalence study.

03

Conditions studied

  • Healthy

Browse trials for

Keywords

  • phenytoin
  • chewable tablets
  • dilantin
  • epanutin
  • infatabs
  • bioequivalence
  • Partial seizure
  • Tonic-clonic seizure
04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and/or female subjects between the ages of 21 and 55 years, inclusive.
  • An document signed and dated by the subject.

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of abnormalities.
  • Any condition possibly affecting drug absorption (e.g. gastrectomy).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Active comparator
    Treatment A

    Epanutin Infatabs 50 mg (sourced from Germany), 1 x 50 mg (REFERENCE)

    Drug: Epanutin Infatabs (Phenytoin)

  • Experimental
    Treatment B

    Dilantin Infatabs 50 mg (sourced from Australia), 1 x 50 mg (TEST)

    Drug: Dilantin Infatabs (Phenytoin)

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

    Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast).

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, and 72 hours (hrs) post-dose

  2. Maximum Observed Plasma Concentration (Cmax)

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48 and 72 hrs post-dose

Secondary outcomes

  1. Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0-∞])

    AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48 and 72 hrs post-dose

  2. Extrapolated Area Under the Curve (AUC Percent [%] Extrap)

    AUC%extrap is the percentage of AUC \[0-∞\] obtained by forward extrapolation. It is calculated as (AUC \[0-∞\] minus AUClast)\*100/ AUC \[0-∞\], where AUC \[0-∞\] = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-∞) and AUClast is area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration.

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48 and 72 hrs post-dose

  3. Plasma Decay Half Life (t1/2)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48 and 72 hrs post-dose

  4. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48 and 72 hrs post-dose

07

Results

Posted Dec 14, 2011

Participant flow

First Intervention Period
Participant flow — First Intervention Period
MilestoneEpanutin Infatabs 50 mg First, Then Dilantin Infatabs 50 mgDilantin Infatabs 50 mg First, Then Epanutin Infatabs 50 mg
Started1313
Completed1311
Not completed02
Withdrew: Adverse event01
Withdrew: Withdrawal by subject01
Washout Period (at Least 7 Days)
Participant flow — Washout Period (at Least 7 Days)
MilestoneEpanutin Infatabs 50 mg First, Then Dilantin Infatabs 50 mgDilantin Infatabs 50 mg First, Then Epanutin Infatabs 50 mg
Started1311
Completed1311
Not completed00
Second Intervention Period
Participant flow — Second Intervention Period
MilestoneEpanutin Infatabs 50 mg First, Then Dilantin Infatabs 50 mgDilantin Infatabs 50 mg First, Then Epanutin Infatabs 50 mg
Started1311
Completed1311
Not completed00

Outcome measures

PrimaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast).

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, and 72 hours (hrs) post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
ng*hr/mLEpanutin Infatabs 50 mgDilantin Infatabs 50 mg
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)21380.0 ± 6043.021370.0 ± 5571.2
Statistical analysis
  • Epanutin Infatabs 50 mg vs Dilantin Infatabs 50 mg · Ratio of adjusted means: 101.33 · 90% CI 97.85 to 104.94
PrimaryMaximum Observed Plasma Concentration (Cmax)
Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48 and 72 hrs post-dose
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax)
ng/mLEpanutin Infatabs 50 mgDilantin Infatabs 50 mg
Maximum Observed Plasma Concentration (Cmax)952.10 ± 229.25976.50 ± 214.78
Statistical analysis
  • Epanutin Infatabs 50 mg vs Dilantin Infatabs 50 mg · Ratio of adjusted means: 102.20 · 90% CI 97.18 to 107.47
SecondaryArea Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0-∞])

AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48 and 72 hrs post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0-∞])
ng*hr/mLEpanutin Infatabs 50 mgDilantin Infatabs 50 mg
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0-∞])21730.0 ± 6345.921740.0 ± 5816.7
Statistical analysis
  • Epanutin Infatabs 50 mg vs Dilantin Infatabs 50 mg · Ratio of adjusted means: 101.43 · 90% CI 97.56 to 105.47
SecondaryExtrapolated Area Under the Curve (AUC Percent [%] Extrap)

AUC%extrap is the percentage of AUC \[0-∞\] obtained by forward extrapolation. It is calculated as (AUC \[0-∞\] minus AUClast)\*100/ AUC \[0-∞\], where AUC \[0-∞\] = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-∞) and AUClast is area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration.

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48 and 72 hrs post-dose
Reported as:
Geometric mean · Percent AUC
Extrapolated Area Under the Curve (AUC Percent [%] Extrap)
Percent AUCEpanutin Infatabs 50 mgDilantin Infatabs 50 mg
Extrapolated Area Under the Curve (AUC Percent [%] Extrap)3.321 ± 4.8843.198 ± 4.805
SecondaryPlasma Decay Half Life (t1/2)

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48 and 72 hrs post-dose
Reported as:
Mean · hr
Plasma Decay Half Life (t1/2)
hrEpanutin Infatabs 50 mgDilantin Infatabs 50 mg
Plasma Decay Half Life (t1/2)14.380 ± 3.24714.970 ± 4.777
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48 and 72 hrs post-dose
Reported as:
Median · hr
Time to Reach Maximum Observed Plasma Concentration (Tmax)
hrEpanutin Infatabs 50 mgDilantin Infatabs 50 mg
Time to Reach Maximum Observed Plasma Concentration (Tmax)3.51 (1.00 to 5.00)4.00 (1.00 to 6.00)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Epanutin Infatabs 50 mg—0/24 (0%)4/24 (16.7%)
Dilantin Infatabs 50 mg—0/26 (0%)2/26 (7.7%)
Most frequent other events
Most frequent other events
EventEpanutin Infatabs 50 mgDilantin Infatabs 50 mg
HeadacheNervous system disorders2/240/26
Upper respiratory tract infectionInfections and infestations1/241/26
DizzinessNervous system disorders1/240/26
RashSkin and subcutaneous tissue disorders0/241/26

Baseline characteristics

Age, Continuous
Age, Continuous(years)Entire Study Population
Mean31.8 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female1
Male25
08

Study locations

1 site
  • Pfizer Investigational Site
    Singapore, 188770, Singapore
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2011, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2011
First posted
May 17, 2011
Start
May 2011
Primary completionActual
Jun 2011
CompletionActual
Jun 2011
Results first posted
Dec 14, 2011
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01355068
Responsible party
Sponsor
First posted
May 17, 2011
Start date
May 2011
Primary completion
Jun 2011
Completion
Jun 2011
Results posted
Dec 14, 2011
Last update
Jan 28, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Phenytoin

Start the discussion